Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock

TheMotleyFool

0 0

As you probably could have guessed, Ozempic and Wegovy aren't going to be the last popular and profitable medicines that Novo Nordisk (NYSE: NVO) will bring to market. Nor is the Danish pharma juggernaut going to focus exclusively on developing more therapies for diabetes and obesity, despite how excellent its performance has been, thanks to its treatments in those indications.

Instead, the company is planning to diversify into yet another key market, and its shareholders are probably going to eventually become a bit richer as a result.

Source Fool.com

Like: 0

NVO

Share